The Correlation Between Self-Care Behavior and The Self-Efficacy of Hypertensive Adults

Introduction: Medication adherence is critical to succesful of hypertension control, and other effort to maintain blood pressure for hypertensive adult is lifestyle modifica­tions involving healthy eating, sodium reduction, and increased physical activity. A person’s behavior to maintain their health condition including their high blood pressure can be affected by their self-efficacy. The purpose of this study is to assess the self-care behavior of hypertensive adults to examine its relationship with the self-efficacy in order to propose inputs to the development of lifestyle program. Methods: The descriptive correlation method of quantitative research utilized in this study. The respondents of this stady consisted of of 120 hypertensive adults. The self-care behavior and self-efficacy of hypertensive adults were assessed use questionnaires and statistically tested with pearson-r. Results: The characteristic of respondents in this study were mostly female (76.7%), age ≥ 60 years old (57.5%), and graduated from Senior High School (59.2%). The pearson-r results showed that the computated T of 4.705 was greater than tabular value of 1.96 so that the null hypothesis was rejected. Conclusions: The characteristic of respondents in this study were mostly female (76.7%), age ≥ 60 years old (57.5%), and graduated from Senior High School (59.2%). There is a significant relationship between self-care bahavior and self-efficacy of hypertensive adults

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio